You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A novel biomaterial based therapy utilizing auto antigen and adjuvant for the amelioration of Type Diabetes

    SBC: ONEVAX, LLC            Topic: NIAID

    Immune mediated diseases such as type diabetes T D multiple sclerosis rheumatoid arthritis and systemic lupus erythematosis are reaching epidemic proportions in the US T D affects an estimated million Americans with more than new patients diagnosed annually resulting in roughly $ B in health care costs in the US each year T D is an autoimmune disease characterized by effector ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. An interactive App to Promote Safe and Effective use of Opioids in Young Children Postoperatively

    SBC: ARCHIE MD INC.            Topic: NIDA

    In recent years increased attention to pain in children and adolescents has led to a recent fold increase in opioid prescriptions Unsurprisingly the annual rates of analgesic related adverse drug events AR ADEs have soared to include andgt hospital admissions and hundreds of accidental overdose deaths in children and adolescents and has remained a significant problem At the heart of ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Biomaterial based delivery of Interleukin to Regulatory T Cells for the amelioration of Type Diabetes

    SBC: ONEVAX, LLC            Topic: NIAID

    Type Diabetes T D results from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producing cells in the pancreas Ultimately glucose metabolism is interrupted resulting in the development of life threatening complications such as heart disease and renal failure T D affects an estimated million Americans with more than new patie ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Biomaterials for mRNA based cellular reprogramming

    SBC: Stem Pharm, Incorporated            Topic: 100

    Project Summary Abstract Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and regenerative medicine and as a result have unique commercial potential There are currently more than ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC derived retinal pigment epithelial cells to treat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Semantic Data Lake for Biomedical Research

    SBC: INFOTECH SOFT, INC.            Topic: 100

    Capitalizing on the transformative opportunities afforded by the extremely large and ever growing volumevelocityand variety of biomedical data being continuously produced is a major challengeThe development and increasingly widespread adoption of several new technologiesincluding next generation genetic sequencingelectronic health records and clinical trials systemsand research data warehouses mea ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing.

    SBC: Specific Diagnostics, Inc.            Topic: NIAID

    Project Summary Antibiotic resistance has recently emerged as a global threat for healthcare systemsAn increasing number of pathogenic bacteria are acquiring antibiotic resistanceand new forms of resistance are continuously emerging with alarming speed across international boundariesIn the USalonethe Center for Disease Control and PreventionCDChas estimatedmillion patients per year are directly af ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Combining faster detection with ID: a new paradigm for mycobacterial culture

    SBC: Specific Diagnostics, Inc.            Topic: NIAID

    Project Summary Abstract TuberculosisTBis one of the leading causes of morbidity and mortality from infectious disease worldwide with an estimatedmillion cases of active TB andmillion deaths from the disease annuallyDespite emerging new technologiesculture remains the gold standard in TB diagnosis and therapeutic monitoringInthe World Health OrganizationWHOrecommended the use of a liquid culturing ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. HTS Assays for Targeting the cGAS STING Pathway in Autoimmune Diseases and Cancer

    SBC: Bellbrook Labs, LLC            Topic: 300

    SUMMARY Cytoplasmic nucleic acids alert the immune system to invading pathogens and trigger a robust type I interferon IFN response via activation of the STING stimulator of interferon genes receptor The sensor for cytoplasmic nucleic acids was recently discovered to be a cyclic GMP AMP synthase which produces a unique cyclic dinucleotide second messenger cGAMP that serves as an agonist fo ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. High Fidelity Linear MicroVector to Clone Complex Problematic and Large DNAs

    SBC: VARIGEN BIOSCIENCES CORPORATION            Topic: 200

    The goal of this research is to dramatically improve the ability to clone and analyze large and unstable DNA fragments We propose to develop a novel linear cloning vector to maximize stability of cloned DNA in the bacterial host The vector will use the replication proteins of the phage Phi to achieve the highest accuracy of replication for all DNA inserts including AT rich repetitive or str ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Automation of MicroC as a CDx for myeloma therapies

    SBC: Lynx Biosciences, Inc.            Topic: 102

    Multiple myeloma MM is a debilitating and currently incurable hematological malignancy While the median survival has increased to years MM patients ultimately relapse and become resistant to therapy Once they reach this stage it is often a trial and error process until an effective therapy can be found Furthermore the MM bone marrow tumor microenvironment plays a significant role in ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government